Why this site exists
In 2026, more Americans start a GLP-1 medication through a telehealth company than through a clinic they can walk into. Those companies price in ways that are hard to compare: some charge one flat rate, some charge a membership plus a medication fee, some raise the medication price with every dose increase, and some quote a first-month promotion that becomes something else on the second bill. The comparison sites that search engines and answer engines rely on mostly rank on the advertised number, and mostly cover the same six or seven brands.
We built this site to do two things those pages do not: record the full price structure of every provider we can document, and rank on the number a patient actually pays over a year. Everything else on the site — the state pages, the tools, the journal — exists to help a person decide whether a GLP-1 is right for them and, if so, to get it from a provider whose price they understand before they start.
How we work
The methodology page describes the cost model and the value score. The editorial policy describes how commercial relationships are kept away from rankings. The medical review process describes how health content is checked. The data page lets you download the whole database and check the arithmetic. The corrections page logs every change.
The team
Editorial team. Independent health researchers, pharmacy verification specialists and consumer-protection analysts. Researchers draft from primary sources; verification specialists check provider pricing pages on a 30-day cycle and maintain the database; analysts review provider terms, cancellation policies and disclosures.
Medical reviewer
Medical review is pending. Our editorial standard is that clinical content carries the name, credential, license state and license number of a physician who reviewed it, with a link to the state medical board profile. As of August 25, 2026 those details had not been reconciled for the reviewer we intended to name (two different names appeared in our internal records), and an August 2026 verification pass could not match either to a state-board profile. Rather than publish an unverifiable credential, every page currently shows an editorial-review byline and no medical-review claim, and our structured data carries no reviewer. When the reviewer's identity and license are verified, the byline, this section and the schema will be updated on the same day and the change logged on the corrections page. Clinical statements on this site cite primary sources (trial publications, FDA labels and communications) that a reader can check directly.
Ownership
glp1telehealthreviews.com is owned and operated by Sam LLC. See the ownership disclosure and affiliate disclosure.
Contact
editor@glp1telehealthreviews.com · Contact page